Detection of anti-colon antibodies in inflammatory bowel disease using human cultured colonic cells.

BACKGROUND

Investigation of anti-colon antibodies may be simplified if a sensitive method and homogeneous source of antigen were available.

AIMS

To examine the anti-colon antibody response using human colonic carcinoma cell lines as antigen.

SUBJECTS

Patients with inflammatory bowel disease and other gastrointestinal disorders and healthy controls were studied.

METHODS

Comparative enzyme linked immunosorbent assays (ELISAs) were performed to assess the value of whole Caco-2, HT-29, and LS-180 cells as antigen. The antigenic determinants of the immune response were characterised by western blot analysis.

RESULTS

Sera demonstrated immunoreactivity against each of the cell lines, but different epitopes were recognised. Applying whole Caco-2 cells as antigen in an ELISA, the prevalence of anti-colon antibodies was significantly greater in patients with ulcerative colitis (36%) than Crohn's disease (13%), other gastrointestinal disorders (13%) and healthy controls (0) (p<0. 05). The immune response was not associated with one predominant antigen.

CONCLUSIONS

Fixed whole cell ELISA is a simple and feasible method for studying the anti-colon antibody response. This response is non-specific, being directed against multiple antigens, and is likely to be an epiphenomenon of inflammatory bowel disease, more so for ulcerative colitis than Crohn's disease.